Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1998-07-01
2002-01-29
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S236100, C424S184100, C514S002600, C530S350000, C530S825000, C530S806000, C435S975000, C435S007200
Reexamination Certificate
active
06342231
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to a cellfree extract preparation of
Haemophilus parasuis,
which has toxic activity. The preparation is useful as a vaccine and as a diagnostic agent for
Haemophilus parasuis.
BACKGROUND OF THE INVENTION
Glässer observed in 1910 a small Gram-negative organism associated with a fibrinous serositis and polyarthritis in swine, which was eventually identified as
H. parasuis
and distinguished taxonomically from
H. suis.
It is now accepted that
H. parasuis
is the infectious agent of porcine polyserositis and arthritis (or Glasser's disease).
H. parasuis
(Hps) is a small pleomorphic Gram-negative rod, varying from a coccobacillary form to slender filaments. Growth is supported only on media containing nicotinamide-adenine dinucleotide (NAD) (heated blood agar, Levinthal agar) or on blood agar in the vicinity of a streak of a Staphylococcus strain (satellitism). Visible growth occurs generally after 36-48 hours incubation.
Porcine polyserositis-arthritis is found worldwide and was historically considered to be a sporadic stress-associated disease of young pigs. More recently, introduction of the pathogen into large populations of specific pathogen free (SPF) herds has shown a devastating effect: infection may spread as a contagious disease of high morbidity, affecting pigs of all ages without obvious associated stress factors. The disease most often affects young pigs (2 weeks to 4 months), principally after the weaning period (5-8 weeks). Mortality may reach 50%.
Serological studies using extracts from autoclaved cells with an agar-gel precipitation test have shown at least fifteen distinct serotypes that differ in their pathogenicity (Kielstein,
J. Clin. Micro.
30:4:862, (1992)).
Vaccines for
H. parasuis
are commercially available, which are made of inactivated bacteria, or bacterins. A disadvantage of bacterin vaccines is that they elicit antibodies against primarily (lipo)polysaccharides that are only specific for a certain serotype of
H. parasuis
and hence are not protective against other
H. parasuis
serotypes. The degree of protection against field infection afforded by bacterin vaccines may also be lower than desired.
Even though not currently available, live attenuated
H. parasuis
vaccines would suffer from the drawbacks normally associated with live vacines, including the risk of inoculating animals with inadequately attenuated pathogens and the possibility that the attenuated bacteria may revert to a pathogenic state resulting in disease in the inoculated animal and spread of the pathogens to other animals.
Thus, there is a need for a
H. parasuis
vaccine which is safe, effective and provides heterologous protection (serotype independent). To this end, the present inventors endeavored to develop an alternative vaccine.
The rapid onset of disease and severity of internal damage suggest that the clinical effects may be caused by the expression of one or more Hps toxin(s). It has been suggested that Hps may induce functional and structural damage to the nasal mucosa by initially associating with the mucous layer and inducing damage to the underlying mucosa by release of one or more toxic compounds (Vahle, J. L., Ph.D. thesis, AAI9626072, 960902, Iowa State University (1996)). The chemical nature of any such toxins and how they exerted their effects was not elucidated.
Gram-negative endotoxin has been studied as a possible virulence factor of
H. parasuis.
Endotoxin is a lipopolysaccharide (LPS) component of the outer membrane of Gram-negative bacteria and is released with bacterial lysis. The study of Amano et al (J. Vet. Med. Sci. Vol. 59, No. 6, 451-455 (1997)) reported that Gram-negative endotoxin levels increased in the blood of pigs with acute septicemia caused by
H. parasuis,
and that
H. parasuis
antigen was found associated with pathological lesions. However, one cannot conclude on the basis of the findings of Amano et al. that it is the endotoxin that is causing the clinical and pathological manifestations of the disease, and the identity of the factor(s) causing the pathological effects of
H. parasuis
infection remains unclear.
It is an object of the present invention to find one or more toxins that contribute to the pathology of
H. parasuis
infection. It is also an object of the present invention to develop vaccines containing the one or more toxins. Finally, it is an object of this invention to use this antigenic material as a reagent in a diagnostic test.
SUMMARY OF THE INVENTION
The present invention provides a novel cellfree extract of
Hemophilus parasuis,
which has toxic activity. This extract causes pathological lesions characteristic of
H. parasuis
infection when administered intraperitoneally to pigs. Thus, the extract appears to contain at least one toxin, which is termed herein HpTx. It is also contemplated that there may be more than one toxin in this extract.
Also provided are vaccines containing the extract, which are effective in providing protection against homologous and heterologous challenge. It is contemplated that vaccines containing the isolated toxin or toxins as the immunogen(s) will provide this same type of protection.
Finally, the extract is useful as a diagnostic tool, and can be used to raise antibodies that can be used as diagnostic reagents to detect
H. parasuis
antigen, or could be used itself as a diagnostic reagent to detect antibodies to
H. parasuis.
Kits for diagnostic tests using these materials are also considered part of the present invention.
REFERENCES:
patent: 5456914 (1995-10-01), Stine et al.
patent: 5534256 (1996-07-01), Potter et al.
patent: 5538733 (1996-07-01), Emery et al.
patent: 5648081 (1997-07-01), van den Bosch
patent: 5858677 (1999-01-01), Forsgren
patent: wo 91/18627 (1991-12-01), None
patent: WO 91/18926 (1991-12-01), None
Rapp-Gabrielson et al. H. parasuis: Immunogenicity and cross-protection between different serovars. In: Proceedings of the American Association of Swine Practitioners, pp. 26-28, 1994.*
Reddy et al. Anal. Biochem. 214: 106-115, 1993.*
Simpson et al. Methods in Enzymol. 165: 76-85, 1988.*
Dasgupta et al. Toxicon 21: 535-545, 1983.*
Niven DF. Can. J. Microbiol. 30: 763-773, 1984.*
Hartmann et al. J. Vet. Med. B 42: 59-63, 1995.*
Charland et al. Can. J. Microbiol. 41: 70-74, 1995.*
Zucker et al. Am. J. Vet. Res. 57: 63-67, 1996.*
Nielsen et al. Nord. Vet. Med. 27: 20-25, 1975.*
Kielstein et al. J. Vet Med. B 38: 315-320, 1991.*
Rapp-Gabrielson et al. In: Proc. 14th International Pif Veterinary Society Congress, IPVS, Bologna, Italy, Jul. 7-10, p. 300 (cited as reference A), 1996.*
Sidorov et al. Soviet Agric. Sci. 8: 44-45, 1980.*
Rapp et al. In: Abstracts of papers presented at the 66th Annual Meeting of the Conference of Research Workers in Animal Disease, Chicago, Illinois, Nov., pp. 45, abstract 245, 1985.*
Hill et al. Agri-Practice 14: 6-9, 1993.*
Solano-Aguilar et al. Am. J. Vet. Res. 60: 81-87, abstract, 1999.*
Awad-Masalmeh et al. In: Proc. 11th Congr. Inter. Pig Vet. Soc. Lausanne, Switzerland, Jul. 1-5, p. 107, 1990.*
Bhatia et al. Vet. Microbiol. 29: 147-158, abstract, 1991.*
Zucker et al. Berliner und Munchener Ticrarztliche Wochenschrift 107: 78-81, abstract, 1994.*
Morton et al. Dissert. Abstr. Inter. vol. 5108B, 1-53, p. 3675, abstract, 1989.*
Weiss et al. J. Vet. Med. Ser. B 34: 109-118, abstract, 1987.*
Neilsen. Acta Veter. Scand. 34: 193-198, 1993.*
Jayappa et al. In: The 29th Annual Meeting of the American Association of Swine Practictioners, AASP, Des Moines, Iowa, pp. 251-254, 1998.*
Rapp-Gabrielson et al. In: Proc. 13th International Pig Veterianry Society Congress, IPVS, Bangkok, Thailand, p. 157, 1994.*
Morton et al. FEMS Mocrobiol. Lett. 65: 123-128, 1989.*
Hikoo et al. Kachiku. Eisei Kenkyu Kaiho (Bull. Animal Hyg.) 35: 7-11, abstract, 1992.*
Akkoyunlu et al: “Distribution of Protein D, an Immunoglobulin D-Binding, Protein, in Haemophilus Strains.” Infection and Immunity (Apr. 1991):59 (4):1231-1238.
Morozumi et al: “Some Antigenic Properties ofHaemophilus parasuisand a Proposal fo
Burkhardt Douglas T.
Lenz Karen L.
Akzo Nobel N.V.
Devi S.
Sullivan Michael G.
LandOfFree
Haemophilus parasuis vaccine and diagnostic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Haemophilus parasuis vaccine and diagnostic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Haemophilus parasuis vaccine and diagnostic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2854716